We are monitoring the impact of COVID-19 on APAC Multiple Sclerosis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12198
Share on
Share on

APAC Multiple Sclerosis Drugs Market Research Report – Segmented By Drug class, Disease type, Route of administration, Distribution channel, & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: September, 2021
ID: 12198
Pages: 100

APAC Multiple Sclerosis Drugs Market Size (2021 to 2026)

The APAC multiple sclerosis drugs Market was worth USD 5.49 billion in 2021 and is estimated to be growing at a CAGR of 9.34%, to reach USD 8.58 billion by 2026.

Multiple sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS), particularly the communication between the brain and other areas of the body.

During the forecast period, the APAC  multiple sclerosis drugs market is expected to develop due to an increase in the number of patients, increasing screening, and the demand for better care alternatives. The disease is more common in older people, thus the rise in the geriatric population is fuelling the expansion of the multiple sclerosis drug market. Clinical research and R&D investment are attracting a lot of attention on the market.

Many pharmaceutical companies are concentrating their efforts on creating new treatments for multiple sclerosis. Increased research efforts have also created the path for a slew of research agreements between pharmaceutical corporations and research institutes, benefiting the industry even more. Increased research on diverse novel candidates has resulted in the pipeline portfolios of both large and small pharmaceutical businesses being strengthened. The anticipated launch of these pipeline candidates is projected to fuel the growth of the APAC multiple sclerosis drugs market. The burden of MS(multiple sclerosis) is growing at an alarming rate, causing anxiety among healthcare practitioners and governments alike.

As the disease's prevalence has increased, several governments have been forced to take proactive steps in the form of guidelines and recommendations. Aside from that, government organizations are launching numerous public awareness campaigns to educate patients about the many treatment alternatives available. For people with MS, the American Academy of Neurology (AAN) has developed a number of guidelines for initiating, switching, and discontinuing disease-modifying treatments (DMTs). Some of the other primary drivers of the MS medicines market are the significant unmet need for therapies to treat the disease and the large R&D pipelines.

Furthermore, increased research in the field of MS to find novel therapeutics has propelled the MS pharmaceuticals market's rise. Several pharmaceutical companies are conducting clinical trials for the treatment of multiple sclerosis. Companies are attempting to develop novel treatments for individuals suffering from multiple sclerosis radiology, which is propelling the APAC multiple sclerosis drugs market forward.

However, The high cost of pharmaceuticals used to treat multiple sclerosis (MS) restricts the market's growth. MS is an incurable disease that requires lifelong treatment due to the significant risk of disability. Despite tight rivalry among pharmaceutical companies, MS(Multiple Sclerosis) drugs remain expensive, increasing the entire cost of treatment. Companies in the multiple sclerosis drugs market are regularly forced to lower the price of these drugs in order to convince their clients of their cost-effectiveness.

This research report on the APAC multiple sclerosis drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers
  • NF-κB Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Adrenocorticotropic Hormone
  • Others

By Disease Type:

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

By Route of Administration:

  • Parenteral
  • Oral

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand, Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

In the APAC Multiple Sclerosis Drug market, Asia is predicted to increase at a rapid pace over the next five years. This is owing to the fact that numerous companies have built manufacturing and research facilities in the area. Low salaries, a huge talent pool, and less rigorous environmental and health, and safety standards provide this country an advantage over developed regions.

Asia's fastest-growing MS(Multiple Sclerosis) drug markets are predicted to include Japan, China, and India. The MS medicines industry would benefit from advancements in biomedical research. Some of the significant trends in the MS medicines market include increased mergers and acquisitions between manufacturing businesses and quick product releases.

KEY MARKET PLAYERS:

Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), and AbbVie, Inc. are a few of the promising companies operating in the APAC multiple sclerosis drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Multiple Sclerosis Drugs Market – By Drug Class:                       

                        6.1.1   Interferon Beta

                        6.1.2 Sphingosine 1 Phosphate Receptor Modulators          

                        6.1.3   Mixed Polymers          

                        6.1.4  NF-κB Inhibitor 

                        6.1.5  Pyrimidine Synthesis Inhibitor 

                        6.1.6  Monoclonal Antibodies

                        6.1.7 Corticosteroids 

                        6.1.8 Adrenocorticotropic Hormone 

                        6.1.9 Others   

                        6.1.10 Market Size Estimations & Forecasts (2021-2026)    

                        6.1.11 Y-o-Y Growth Rate Analysis    

                        6.1.12 Market Attractiveness Index  

            6.2 Multiple Sclerosis Drugs Market – By Disease Type:                  

                        6.2.1 Relapsing-remitting MS (RRMS)

                        6.2.2 Primary-progressive MS (PPMS)          

                        6.2.3 Secondary-progressive MS (SPMS)      

                        6.2.4    Progressive-relapsing MS (PRMS)      

                        6.2.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.6 Y-o-Y Growth Rate Analysis      

                        6.2.7 Market Attractiveness Index    

            6.3 Multiple Sclerosis Drugs Market – By Route of Administration:             

                        6.3.1  Parenteral        

                        6.3.2   Oral     

                        6.3.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.4 Y-o-Y Growth Rate Analysis      

                        6.3.5 Market Attractiveness Index    

            6.4 Multiple Sclerosis Drugs Market – By Distribution Channel:                  

                        6.4.1    Hospital Pharmacies  

                        6.4.2  Retail Pharmacies & Drug Stores         

                        6.4.3 Online Pharmacies        

                        6.4.4 Market Size Estimations & Forecasts (2021-2026)      

                        6.4.5 Y-o-Y Growth Rate Analysis      

                        6.4.6 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 Asia Pacific                       

                        7.1.1 By Country        

                                    7.1.1.1 China

                                    7.1.1.2 India

                                    7.1.1.3 Japan

                                    7.1.1.4 South Korea

                                    7.1.1.5 South East Asia

                                    7.1.1.6 Australia & NZ

                                    7.1.1.7 Rest of Asia-Pacific

                        7.1.2  By Drug Class:  

                        7.1.3 By Disease Type:           

                        7.1.4 By Route of Administration:     

                        7.1.5 By Distribution Channel:           

8. Key Player Analysis                        

            8.1 Bayer AG              

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Teva Pharmaceutical Industries Ltd.                   

            8.3  Novartis AG                     

            8.4 Sanofi                   

            8.5  F. Hoffmann-La Roche Ltd.                     

            8.6 Celgene Corporation                   

            8.7 Acorda Therapeutics, Inc.            

            8.8 Biogen, Inc.                      

            8.9 Actelion Pharmaceuticals (Johnson & Johnson)             

            8.10 EMD Serono (Merck KGaA)                   

            8.11 AbbVie, Inc.                    

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures 

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug class, disease type, route of administration, distribution channel and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Asia Pacific multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  2. Asia Pacific Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )

  3. Asia Pacific Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )

  4. Asia Pacific   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )

  5. Asia Pacific NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  6. Asia Pacific Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  7. Asia Pacific Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )

  8. Asia Pacific Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )

  9. Asia Pacific Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )

  10. Asia Pacific  Others Market By Region, From 2021 to 2026 ( USD Billion )

  11. Asia Pacific multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  12. Asia Pacific Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  13. Asia Pacific Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  14. Asia Pacific  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  15. Asia Pacific Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  16. Asia Pacific multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  17. Asia Pacific Parenteral Market By Region, From 2021 to 2026 ( USD Billion )

  18. Asia Pacific Oral Market By Region, From 2021 to 2026 ( USD Billion )

  19. Asia Pacific multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  20. Asia Pacific Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  21. Asia Pacific Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )

  22. Asia Pacific  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  23. Japan multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  24. Japan multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  25. Japan multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  26. Japan multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  27. China multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  28. China multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  29. China multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  30. China multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  31. India multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  32. India multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  33. India multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  34. India multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  35. Australia multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  36. Australia multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  37. Australia multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  38. Australia multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  39. South Korea multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  40. South Korea multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  41. South Korea multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  42. South Korea multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample